Genetic Epidemiology of Porcine Epidemic Diarrhea Virus Circulating in China From 2010 to 2024: Characterization of Phylogenetic and Genetic Diversity of S1‐Based Genes

Journal of Medical Virology, Journal Year: 2025, Volume and Issue: 97(2)

Published: Feb. 1, 2025

ABSTRACT As a porcine alphacoronavirus , epidemic diarrhea virus (PEDV) frequently undergoes mutations that significantly reduce the effectiveness of current prevention and control strategies, leading to recurrent outbreaks in China. This study investigates genetic evolution mutation patterns S1 protein characterize PEDV variation Genetic evolutionary analysis 804 genes, including 620 Chinese strains, revealed 78.06% strains belong G2a‐subgroup, further divided into seven branches (G2a‐Clade 1–7), with predominant from 2020 2024 being G2a‐Clade 4 (68.00%). From 2021 2024, 32 novel substitutions, 25 deletions, 8 insertions were identified compared those 2010 2011. Notably, complete observed at amino acid sites N139D, H189Y, L229P, I287M, F345L, A361T, T499I, A520S. Moreover, homology modeling displayed these deletion–insertion altered surface structure S protein, particularly N‐terminal domain (NTD) receptor‐binding (RBD) regions protein. The predictive using AlphaFold3 indicated S1‐RBD region notably affected binding affinity DC‐SIGN. These findings enhance our understanding

Language: Английский

---

Early nintedanib deployment in COVID-19 interstitial lung disease (ENDCOV-I): study protocol of a randomised, double-blind, placebo-controlled trial

BMJ Open Respiratory Research, Journal Year: 2025, Volume and Issue: 12(1), P. e002323 - e002323

Published: April 1, 2025

Introduction In December 2019, the novel SARS-CoV-2 triggered a global pneumonia outbreak, leading to millions of deaths worldwide. A subset survivors faces increased morbidity and mortality, particularly due subacute lung injury evolving chronic fibrosing interstitial disease. While nintedanib, tyrosine-kinase inhibitor, shows promise in treating progressive fibrotic disease, limited randomised trial data exists for post-COVID-19-induced injury. We hypothesise that treatment with nintedanib may attenuate advancement stages, offering potential avenue improving outcomes this specific patient subset. Methods analysis describe design multicentre, randomised, double-blind, placebo-controlled involving approximately 170 patients secondary COVID-19, who required respiratory support oxygen supplementation. Patients are by site disease phenotype (fibrotic vs non-fibrotic) 1:1 ratio either oral or placebo. will be followed 180 days. The primary endpoint is assess change from baseline forced vital capacity (FVC, mL) at Secondary objectives include FVC (mL) 90 days; diffusing carbon monoxide (% predicted) 6-min walk test (feet) mortality Qualitative quantitative changes high-resolution computerised tomography (HRCT), patient-reported outcome measures (PROMs) safety endpoints also assessed. Analysis performed according intention-to-treat principle. Ethics dissemination study conducted accordance Good Clinical Practices as outlined Food Drug Administration Declaration Helsinki 2008. This received approval participating sites’ Institutional Review Boards committees, including Committee Medical Board Mount Sinai Hospital (ID: HS#20–01166). Independent Oversight oversees conduct, duration investigation. details presented align protocol V.8. (April 2022). Results national international conferences, published peer-reviewed journal disseminated patients, funders researchers on completion. Trial registration number NCT04619680 . First posted 6 November 2020.

Language: Английский

---

Structural basis for the participation of the SARS-CoV-2 nucleocapsid protein in the template switch mechanism and genomic RNA reorganization

Journal of Biological Chemistry, Journal Year: 2024, Volume and Issue: unknown, P. 107834 - 107834

Published: Sept. 1, 2024

Language: Английский

---

Targeting the Ca2+ signaling toolkit as an alternative strategy to mitigate SARS-CoV-2-induced cardiovascular adverse events

Vascular Pharmacology, Journal Year: 2024, Volume and Issue: unknown, P. 107458 - 107458

Published: Dec. 1, 2024

Language: Английский

---